Samil Pharmaceutical will receive exclusive rights to develop and commercialize ZERVIATE in South Korea, where the market for allergic conjunctivitis was worth nearly €31 million for the 12 months to Q3 2019.
French ophthalmology firm Nicox has partnered with China-based Ocumension Therapeutics to develop and commercialise its NCX 470 for the treatment of patients with glaucoma or ocular hypertension......
Nicox has pulled out of a planned Nasdaq listing. The French biotech began gearing up to offer stock on Nasdaq earlier this year but has now hit pause on the plan in response to ...